Stock Events

Stock Events

Benitec Biopharma 

€3.06
19
+€0+0% Monday 07:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 18
€0.03
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.78
-0.59
-0.41
-0.22
Expected EPS
-0.275
Actual EPS
N/A

Financials

-25,091.44%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
65,316.7Revenue
-16.39MNet Income

Analyst Ratings

20.49Average Price Target
The highest estimate is 24.28.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BJ93.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.12B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the broader genetic treatment market.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap287.74M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Show more...
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Employees
18
Country
United States
ISIN
US08205P1003
WKN
000A2P06Q

Listings

MU
DE
BJ93.MU
STU
DE
BJ93.STU
XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BJ93.F is €3.06 EUR — it has increased by +0% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Benitec Biopharma stocks are traded under the ticker BJ93.F.
What is Benitec Biopharma revenue for the last year?▼
Benitec Biopharma revenue for the last year amounts to 65,316.7 EUR.
What is Benitec Biopharma net income for the last year?▼
BJ93.F net income for the last year is -16.39M EUR.
Does Benitec Biopharma pay dividends?▼
Yes, BJ93.F dividends are paid en. The last dividend per share was 0.04 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Benitec Biopharma have?▼
As of April 16, 2026, the company has 18 employees.
In which sector is Benitec Biopharma located?▼
Benitec Biopharma operates in the Health & Wellness sector.
When did Benitec Biopharma complete a stock split?▼
Benitec Biopharma has not had any recent stock splits.
Where is Benitec Biopharma headquartered?▼
Benitec Biopharma is headquartered in Hayward, United States.